Comparison of Repaglinide and Nateglinide in Combination with Mefformin: Response to Raskin et al. [12] (multiple letters)

Diabetes Care

Volumn 26, Issue 12, 2003, Pages 3361-3363

  Baron, Michelle A ^a   Raskin, Philip ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METFORMIN; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA;

DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LETTER; PATIENT; TITRIMETRY;

CARBAMATES; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PHENYLALANINE; PIPERIDINES;

EID: 0345707485     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.12.3361     Document Type: Letter

References (0)